ALLR
Get informed when a big investor buys or sells
+ FollowUndervalued by 23.2% based on the discounted cash flow analysis.
| Market cap | $13.77 Million |
|---|---|
| Enterprise Value | $-3,131,859.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.78 |
| Beta | 0.57 |
| Outstanding Shares | 15,910,724 |
| P/E Ratio | -1.11 |
|---|---|
| PEG | -2.37 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -9.08 |
| Enterprise Value to EBIT | 0.29 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | -0.03 |
| Debt to Equity | 0.02 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Stockcircle tracks 2 top investors with a current 13F position in Allarity Therapeutics. Holdings come from the latest quarterly 13F filings filed with the SEC.
In the latest 13F quarter on Stockcircle, 2 top investors increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.